Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib.
Phase of Trial: Phase IV
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Biomarker; Therapeutic Use
- Acronyms STIM-2
- 12 Mar 2018 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 22 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.